UMP Healthcare Holdings Limited
HHKEX:7220.39
HKD
+0.00
(-1.27%)
ISIN
KYG9320W1069
CUSIP
G9320W106
Return %
Stock
S&P 500
1Y
-17.89
14.20
3Y
-43.48
81.12
5Y
-53.57
68.34
Capital Structure
HKD
•
in mil. unless spec.Working Capital
HKD
•
in mil. unless spec.Growth Rates
HKD
•
in mil. unless spec.Semi-annual Revenue
HKD
•
in mil. unless spec.Semi-annual Earnings Per Share
HKD
•
in mil. unless spec.Semi-annual Dividends Per Share
HKD
•
in mil. unless spec.Company Description
- CEO
- Cheuk Kwan Kwok
- Full Time Employees
- 494
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Wing On House Hong Kong Hong Kong
- IPO Date
- Nov 27, 2015
- Website
- ump.com.hk
- Similar Companies
- Business
- UMP Healthcare Holdings Limited (722.HK), an investment holding company founded in 1990 and headquartered at 27/F, Wing On House, 71 Des Voeux Road Central, Hong Kong, operates as a leading comprehensive healthcare services platform in Hong Kong, Macau and Mainland China, providing multidisciplinary medical and healthcare services through over 1,000 self-owned and affiliated network service points to insurance companies, corporations, self-paid patients and government schemes. The company offers general practice and family medicine; specialist consultations encompassing internal medicine, surgery, paediatrics, cardiology, dermatology, otorhinolaryngology, orthopaedics, ophthalmology, urology, gastroenterology and hepatology, radiology, endocrinology, diabetes, neurology, neurosurgery, obstetrics and gynaecology, geriatrics, respiratory medicine, rheumatology and clinical oncology; dental care including implants, cosmetic dentistry, periodontal treatments, orthodontics and traditional Chinese medicine; physiotherapy services such as muscle-strengthening, limb function, eye-hand coordination and hand function training; day surgery and endoscopy; diagnostic imaging and laboratory testing; preventive medicine and health assessments; visa medical examinations; vaccinations; vision care and optometry; plastic, head and neck surgeries; medical cosmetics, dermatology and aesthetics; chronic disease management for hypertension, cardiovascular disease, diabetes and joint diseases; corporate healthcare solutions and third-party administration services; as well as the WeWell Healthcare platform for family health management, health checkups, vaccinations and specialist referrals. It conducts operations across three main segments: Hong Kong and Macau Corporate Healthcare Solution Services; Hong Kong and Macau Clinical Healthcare Services, which generates the majority of revenue; and Mainland China Clinical Healthcare Services. Recent developments include the completion in 2024 of a strategic acquisition of 60% equity in a target company, establishing it as a non-wholly owned subsidiary with a subsequent settlement deed for profit guarantee shortfalls approved by the board; securing government contracts such as nurse clinics, physiotherapy under the Chronic Disease Co-Care Pilot Scheme, and imaging and dental services for Hospital Authority and civil servant referrals; investments in digital transformation with a new patient management system rollout and AI applications in imaging diagnostics; cost-control measures including service location consolidation and resource reallocation that drove a 14.6% year-on-year increase in interim profit attributable to shareholders to HK$17.9 million for the six months ended 31 December 2024 despite a 1.2% revenue dip to HK$371.3 million; and recognition with awards like the Gold Medal for Outstanding Medical Group in 2024 by HK01 and Listed Company Awards of Excellence by Hong Kong Economic Journal.